MS SC539

Urges the U.S. Food and Drug Administration to publish good manufacturing guidelines for kratom manufacturers to restrict adulteration and protect consumers

Calls for banning synthetic enhancement of kratom's natural alkaloid contents to alter the overall alkaloid fraction present in the natural plant

Requires appropriate labeling of kratom products to ensure consumer safety

Notes that HHS rescinded its recommendation to classify kratom as a Schedule I substance after FDA failed to provide sufficient evidence for scheduling

Cites peer-reviewed research indicating kratom helps relieve opioid withdrawal symptoms, with 35% of users free from opioids within a year